loading page

Faster, cheaper and under control: de-risking CMC development with transposon-derived manufacturing cell lines
  • +12
  • Sowmya Rajendran,
  • Sowmya Balasubramanian,
  • Lynn Webster,
  • Maggie Lee,
  • Divya Vavilala,
  • Nicolay Kulikov,
  • Jessica Choi,
  • Calvin Tang,
  • Molly Hunter,
  • Rebecca Wang,
  • Harpreet Kaur,
  • Surya Karunakaran,
  • Varsha Sitaraman,
  • Jeremy Minshull,
  • Ferenc Boldog
Sowmya Rajendran
ATUM

Corresponding Author:[email protected]

Author Profile
Sowmya Balasubramanian
ATUM
Author Profile
Lynn Webster
ATUM
Author Profile
Maggie Lee
ATUM
Author Profile
Divya Vavilala
ATUM
Author Profile
Nicolay Kulikov
ATUM
Author Profile
Jessica Choi
ATUM
Author Profile
Calvin Tang
ATUM
Author Profile
Molly Hunter
ATUM
Author Profile
Rebecca Wang
ATUM
Author Profile
Harpreet Kaur
ATUM
Author Profile
Surya Karunakaran
ATUM
Author Profile
Varsha Sitaraman
ATUM
Author Profile
Jeremy Minshull
ATUM
Author Profile
Ferenc Boldog
ATUM
Author Profile

Abstract

The development of highly productive, genetically stable manufacturing cell lines is on the critical path to IND filing for protein based biologic drugs. Here we describe Leap-In Transpoasase® platform, a novel transposon-based mammalian (e.g. CHO) cell line development system that produces high titer stable pools with productivity and product quality attributes that are highly comparable to clones that are subsequently derived therefrom. The productivity distributions of clones are strongly biased towards high producers and both genetic and expression stability is consistently high. By avoiding the poor integration rates, concatemer formation, detrimental transgene recombination, low average expression level, unpredictable product quality and inconsistent genetic stability characteristic of non-homologous recombination methods, Leap-In provides several opportunities to de-risk programs early and reduce timelines and resources.
30 Jul 2020Submitted to Biotechnology and Bioengineering
30 Jul 2020Submission Checks Completed
30 Jul 2020Assigned to Editor
03 Sep 2020Reviewer(s) Assigned
15 Oct 2020Review(s) Completed, Editorial Evaluation Pending
15 Oct 2020Editorial Decision: Revise Major
08 Jan 20211st Revision Received
09 Jan 2021Submission Checks Completed
09 Jan 2021Assigned to Editor
12 Jan 2021Reviewer(s) Assigned
05 Feb 2021Review(s) Completed, Editorial Evaluation Pending
05 Feb 2021Editorial Decision: Accept